Contemporary Treatment of Classical Trigeminal Neuralgia in Adults (Literature Review)
DOI:
https://doi.org/10.31149/ijimm.v4i5.2916Keywords:
Classical Trigeminal Neuralgia, Carbamazepine, Oxcarbazepine, Microvascular Decompression, Stereotactic Radiosurgery, Balloon Compression, Radiofrequency Thermocoagulation, Glycerol Rhizolysis, Botulinum Toxin AAbstract
Classical trigeminal neuralgia is one of the most severe pain disorders in clinical neurology, yet its treatment pathway is more coherent than in many other neuropathic pain states. Current literature supports a stepwise model that begins with careful clinical diagnosis and magnetic resonance imaging, moves first through sodium channel blocker therapy, and then shifts early toward surgery when pain control is incomplete or drug toxicity becomes limiting.Carbamazepine and oxcarbazepine remain the core medical treatments because they produce high initial response rates, but long term care is frequently constrained by sedation, dizziness, imbalance, hyponatremia, and other adverse effects rather than by true late loss of efficacy.
References
[1] L. Bendtsen et al., “European Academy of Neurology guideline on trigeminal neuralgia,” European Journal of Neurology, vol. 26, Apr. 2019, doi: 10.1111/ene.13950.
[2] L. Bendtsen et al., “Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia.” The Lancet. Neurology, vol. 19 9, pp. 784–796, Sep. 2020, doi: 10.1016/s1474-4422(20)30233-7.
[3] G. Lambru, J. Zakrzewska, and M. Matharu, “Trigeminal neuralgia: a practical guide,” Practical Neurology, vol. 21, pp. 392–402, Jun. 2021, doi: 10.1136/practneurol-2020-002782.
[4] M. Chong, A. Bahra, and J. Zakrzewska, “Guidelines for the management of trigeminal neuralgia,” Cleveland Clinic Journal of Medicine, vol. 90, pp. 355–362, Jun. 2023, doi: 10.3949/ccjm.90a.22052.
[5] G. Cruccu et al., “AAN‐EFNS guidelines on trigeminal neuralgia management,” European Journal of Neurology, vol. 15, Oct. 2008, doi: 10.1111/j.1468-1331.2008.02185.x.
[6] G. D. Stefano, S. L. Cesa, A. Truini, and G. Cruccu, “Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain,” The Journal of Headache and Pain, vol. 15, pp. 34–34, Jun. 2014, doi: 10.1186/1129-2377-15-34.
[7] G. D. Stefano et al., “Real‐world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia,” European Journal of Pain, vol. 25, pp. 1064–1071, Jan. 2021, doi: 10.1002/ejp.1727.
[8] F. Barker, P. Jannetta, D. Bissonette, M. Larkins, and H. Jho, “The long-term outcome of microvascular decompression for trigeminal neuralgia.” The New England journal of medicine, vol. 334 17, pp. 1077–83, Apr. 1996, doi: 10.1056/NEJM199604253341701.
[9] K. G. Holste, A. Chan, J. Rolston, and D. J. Englot, “Pain Outcomes Following Microvascular Decompression for Drug-Resistant Trigeminal Neuralgia: A Systematic Review and Meta-Analysis.” Neurosurgery, Mar. 2019, doi: 10.1093/neuros/nyz075.
[10] D. D. Wang et al., “Prospective comparison of long-term pain relief rates after first-time microvascular decompression and stereotactic radiosurgery for trigeminal neuralgia.” Journal of neurosurgery, vol. 128 1, pp. 68–77, 2018, doi: 10.3171/2016.9.JNS16149.
[11] I. Noorani, A. Lodge, A. Durnford, G. Vajramani, and O. Sparrow, “Comparison of first-time microvascular decompression with percutaneous surgery for trigeminal neuralgia: long-term outcomes and prognostic factors,” Acta Neurochirurgica, vol. 163, pp. 1623–1634, Mar. 2021, doi: 10.1007/s00701-021-04793-4.
[12] P. Texakalidis, D. Xenos, M. S. Tora, J. S. Wetzel, and N. Boulis, “Comparative safety and efficacy of percutaneous approaches for the treatment of trigeminal neuralgia: A systematic review and meta-analysis.” Clinical neurology and neurosurgery, vol. 182, pp. 112–122, Jul. 2019, doi: 10.1016/j.clineuro.2019.05.011.
[13] J. Régis et al., “Long-term safety and efficacy of Gamma Knife surgery in classical trigeminal neuralgia: a 497-patient historical cohort study.” Journal of neurosurgery, vol. 124 4, pp. 1079–87, Apr. 2016, doi: 10.3171/2015.2.JNS142144.
[14] A. A. Dhople, J. R. Adams, W. Maggio, S. Naqvi, W. Regine, and Y. Kwok, “Long-term outcomes of Gamma Knife radiosurgery for classic trigeminal neuralgia: implications of treatment and critical review of the literature. Clinical article.” Journal of neurosurgery, vol. 111 2, pp. 351–8, Jul. 2009, doi: 10.3171/2009.2.JNS08977.
[15] M. E. Morra et al., “Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials,” The Journal of Headache and Pain, vol. 17, Jul. 2016, doi: 10.1186/s10194-016-0651-8.
[16] X. Hu et al., “Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Trigeminal Neuralgia,” The Clinical Journal of Pain, vol. 40, pp. 383–392, Feb. 2024, doi: 10.1097/AJP.0000000000001207.
[17] J. Zakrzewska et al., “Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.” The Lancet. Neurology, vol. 16 4, pp. 291–300, Apr. 2017, doi: 10.1016/S1474-4422(17)30005-4.
